Although the anti-tumour mechanism of action of metformin is not yet clear [24], its anti-tumour effects in breast cancer are suggested to be via an indirect pathway by decreasing both insulin plasma levels and inhibiting downstream PI3K and mitogen-activated protein kinase (MAPK) signalling. This evidence concerns the gene INS and neoplasm.